Neuroendocrine prostate cancer (NEPC) has increasingly become a clinical challenge. The mechanisms by which neuroendocrine (NE) cells arises from prostate adenocarcinoma cells are poorly understood. FOXA1 is a transcription factor of the forkhead family that is required for prostate epithelial differentiation. In this study, we demonstrated that FOXA1 loss drives NE differentiation, demarcated by phenotypical changes and NEPC marker expressions. Mechanistically, this is mediated by FOXA1 binding to the promoter of interleukin 8 (IL-8), a chemokine previously shown elevated in NEPC, to directly inhibit its expression. Further, IL-8 upregulation activates the MAPK/ERK pathway, leading to ERK phosphorylation and enolase 2 (ENO2) expression. IL-8 knockdown or ERK inhibition, on the other hand, abolished FOXA1 loss-induced NE differentiation. Analysis of xenograft mouse models confirmed FOXA1 loss in NEPC tumors relative to its adenocarcinoma counterparts. Importantly, FOXA1 is downregulated in human NEPC tumors compared to primary and castration-resistant prostate cancers, and its expression is negatively correlated with that of ENO2. These findings indicate that FOXA1 transcriptionally suppresses IL-8, the expression of which would otherwise stimulate the MAPK/ERK pathway to promote NE differentiation of prostate cancer cells. Our data strongly suggest that FOXA1 loss may play a significant role in enabling prostate cancer progression to NEPC, whereas IL-8 and MAPK/ERK pathways may be promising targets for therapeutic intervention.
INTRODUCTION
Prostate cancer (PCa) is the most commonly diagnosed non-skin cancer in the American men. Localized and regional PCas are well managed with surgical and radiation treatments. Metastatic PCa is commonly treated with androgen deprivation therapy and yet resistance develops quickly leading to castration-resistant prostate cancer (CRPC). 1 High-affinity androgen receptor (AR) antagonists, such as abiraterone and enzalutamide, have recently been developed to further inhibit CRPC. Albeit effective in the short term, their use has been associated with increased incidences of neuroendocrine prostate cancer (NEPC) lately. 2, 3 This is consistent with previous reports that long-term androgen depletion causes neuroendocrine (NE) differentiation of PCa cell lines. 4, 5 NEPC tumors are often negative of AR, but instead express NE markers such as enolase 2 (ENO2), chromogranin A and synaptophysin. 6 NEPC tumors are androgen-independent and there are limited treatment options available; platinum-and cisplatin-based therapies are often used, but prognosis remains dismal. 7, 8 It was estimated that the median survival of NEPC patients is only 9.8-13.1 months, compared to 125 months for prostate adenocarcinoma. 9 The molecular basis by which NEPC arises from prostate adenocarcinoma is not fully understood. , is one of the first few molecules implicated in PCa progression to NEPC. 5, 10 IL-8 is a CXC chemokine that binds to its G-proteincoupled receptors CXCR1 and CXCR2, all of which have been shown upregulated in androgen-independent PCa. 11 Further, immunohistochemistry experiments showed that IL-8 is expressed specifically by the NE tumor cells in the human PCa tissues, which also express the CXCR2 receptor. 12, 13 IL-8 stimulates CXCR2 receptor through autocrine signaling to regulate the differentiation or function of NE cells. Blockade of CXCR2 using a smallmolecule antagonist has been shown to decrease androgenindependent PCa cell growth. 14 Besides, IL-8, IL-6, intracellular cyclic AMP and heparin-binding epidermal growth factor-like growth factor have all been shown to induce neuron-like morphology of PCa cells. [15] [16] [17] [18] Their changes in the tumor microenvironment were shown to induce NE differentiation through STAT3 and MAPK/ERK signal transduction pathways. For example, STAT3 expression and function were found to be required for IL-6-induced LNCaP cell NE differentiation, 19 whereas heparin-binding epidermal growth factor-like growth factor induces NE differentiation by activating MAPK/ERK pathway, independently of STAT3 phosphorylation. Further, androgen depletion was also shown to activate MAPK/ ERK in androgen-sensitive LNCaP cells. 20 An MEK inhibitor, PD98059, efficiently blocks NE differentiation of androgendepleted cells, whereas the expression of constitutively active MEK drives NE-like differentiation of LNCaP cells in the presence of androgen.
FOXA1 is a transcription factor that is essential for the development and differential of epithelial cells including the pancreas, liver, breast and prostate. [21] [22] [23] [24] [25] FOXA1 knockout mice are embryonic lethal, but conditional knockout are viable and have been shown to inhibit prostate morphogenesis and epithelial cell differentiation. 24, 26, 27 Furthermore, a recent study reported that prostate-specific deletion of FOXA1 in adult murine epithelium causes prostatic hyperplasia and alteration of differentiated phenotype. 27 Moreover, we reported that loss of FOXA1 leads to AR reprogramming 28 and epithelial-to-mesenchymal transition through direct regulation of SLUG expression. 29 Recent molecular characterization of NEPC tumors have begun to identify important regulators of NEPC, including DEK, 30 
SRRM4
, 31 AURKA and MYCN, 32 as well as epigenetic modifiers such as EZH2. 33 In the present study, we demonstrated that FOXA1 reduces MAPK/ERK activation and prevents NE differentiation of PCa cells. Mechanistically, this is mediated through FOXA1 binding to the promoter of the IL-8 gene to directly inhibit its expression, which is essential for MAPK/ERK inhibition. Our data thus establish FOXA1 as a major regulator of NEPC, and that FOXA1 loss drives CRPC progression or trans-differentiation towards NEPC. Further, our findings support that IL-8/CXCR2-targeting agents and MAPK/ERK inhibitors may be useful in suppressing NEPC.
RESULTS

FOXA1 inhibits NE differentiation of PCa cells
NEPC has increasingly become a major clinical challenge. 3 To determine whether FOXA1, a regulator of epithelial differentiation, is disrupted in NEPC, we analyzed the publically available data set profiling gene expression of patient-derived xenograft modeling the progression from prostatic adenocarcinoma to NEPC. 34 Our data showed that FOXA1 started to decrease at 1 week post castration and was remarkably downregulated in relapsed and NEPC cells, wherein ENO2 was markedly upregulated (Figures 1a  and b) , suggesting a potential role of FOXA1 loss in NEPC progression. To test this, we performed FOXA1 depletion in LNCaP prostate adenocarcinoma cells over a time course using short hairpin RNA-mediated knockdown and puromycin selection. After 1 week of puromycin selection, FOXA1-knockdown cells manifested clear morphological changes towards NE phenotype with multiple neurite extensions, whereas the control cells remained the rounded shape of epithelial cells (Figure 1c ). Nearly 96% of the control cells exhibited the rounded epithelial phenotype, whereas 78% of the FOXA1-depleted cells displayed the NE phenotype, indicating a transition of LNCaP adenocarcinoma cells to NEPC. Stable overexpression of FOXA1, on the other hand, converted NElike PC-3M cells to the rounded shape forming typical epithelial cell clusters (Figure 1d ). Moreover, analysis of gene expression showed that, upon stable FOXA1 knockdown, ENO2 expression was induced at both messenger RNA (mRNA) and protein levels in LNCaP (Figure 1e ) and C4-2B (Figure 1f ) cells compared to their respective control cells. Of note, AR levels were not significantly altered by FOXA1 depletion, precluding its potential regulation of ENO2 (Supplementary Figure 1) . Conversely, we demonstrated that FOXA1 overexpression in PC-3M cells inhibited ENO2 mRNA and protein levels (Figure 1g ). Taken together, our data strongly suggest that FOXA1 is a negative regulator of PCa progression to NEPC. FOXA1 reduces ERK phosphorylation To identify potential mechanisms by which FOXA1 regulates NEPC, we examined whether FOXA1 regulates the MAPK/ERK, cyclic AMP, JAK/STAT3 or PI3K/AKT signaling pathways, as they have been previously associated with NE differentiation. 18, 19, 35 We retrieved corresponding pathway signature gene sets from the Molecular Signature Database and examined their rank-ordered regulation in the expression microarray data comparing control and FOXA1-knockdown cells. Gene set enrichment analysis revealed that MAPK/ERK (false discovery rate, qo 0.001) and JAK/STAT3 (false discovery rate, qo 0.001) pathway genes were enriched for upregulation upon FOXA1 knockdown, whereas no significant enrichment was observed for other the cyclic AMP and PI3K pathways (Figure 2a) . To confirm this, we performed western blot analysis of the MAPK/ERK and JAK/STAT3 pathways in LNCaP cells with control or FOXA1 knockdown. Our data showed that FOXA1 depletion markedly induced pERK level, but pSTAT3 level remains undetectable (Figure 2b ). Similar results were also observed in additional PCa cell lines C4-2B following FOXA1 knockdown (Figure 2c ). In contrast, FOXA1 stable overexpression in PC-3M cells significantly inhibited ERK1/2 phosphorylation, further supporting the MAPK/ERK pathway as the candidate downstream mediator of FOXA1 (Figure 2d ). FOXA1 directly inhibits IL-8 gene expression Next, we sought to examine how FOXA1 activates MAPK/ERK pathway. As FOXA1 is primarily known as a transcription factor, we wondered whether FOXA1 might regulate the transcription of some upstream regulators of the MAPK/ERK pathway. To identify direct FOXA1 targets that could induce ERK phosphorylation, we integrated multiple data sets to identify genes meeting the following selection criteria: (1) were differentially expressed by at least fivefold between LNCaP pGIPZ and shFOXA1 cells by microarray profiling; (2) harbored at least one FOXA1-binding site within the regulatory regions based on LNCaP FOXA1 chromatin immunoprecipitation (ChIP) sequencing data, and (3) belong to the MAPK/ERK pathway. Through overlapping analysis, we obtained 13 genes, among which only 2 genes, CXCL10 and IL-8, were previously identified as upstream regulators of the MAPK/ ERK pathway [36] [37] [38] ( Figure 3a ). As most of prostate cell lines do not express the CXCL10 receptor CXCR3, we decided to focus on IL-8.
To validate the bioinformatics results, we examined IL-8 expression in LNCaP and C4-2B cells with stable FOXA1-knockdown and PC-3M cells with stable FOXA1 overexpression. Importantly, FOXA1 knockdown lead to a significant increase in IL-8 mRNA levels in both LNCaP and VCaP cells (Figure 3b ), whereas FOXA1 overexpression in PC-3M cells remarkably abolished IL-8 expression (Figure 3c ). Furthermore, as IL-8 is a secreted protein, we measured IL-8-secreted protein in cell culture media using enzyme-linked immunosorbent assay (ELISA) and confirmed the increase of IL-8 at protein level in both LNCaP and C4-2B cells following FOXA1 stable knockdown ( Figure 3d ).
Next, we confirmed FOXA1 occupancy at the IL-8 promoter by examining LNCaP FOXA1 ChIP sequencing, which showed that FOXA1 is strongly enriched at the IL-8 promoter (Figure 3e ). To validate the ChIP sequencing result, we performed ChIPuantitative PCR (qPCR) analysis using primers flanking the promoter of the IL-8 gene. Our results validated strong FOXA1 binding at the IL-8 promoter, the enrichment is equivalent or higher than FOXA1 occupancy at the positive control loci-the prostate specific antigen (PSA) enhancer ( Figure 3f ). As a negative control, the KIAA0066 gene was not enriched for FOXA1 binding. To further ensure the binding specificity, we performed FOXA1 ChIP in LNCaP pGIPZ control and shFOXA1 cells. ChIP-qPCR analysis demonstrated significantly decreased amount of FOXA1 occupancy at the IL-8 promoter following FOXA1 knockdown ( Figure 3g ). Furthermore, to determine whether FOXA1 binding at IL-8 promoter holds true in primary PCa tissues, we performed FOXA1 ChIP in localized and metastatic PCa tissues. ChIP-enriched DNA was subjected to ligation-mediated PCR and potential enrichment of a specific genomic region was evaluated relative to the same amount of input DNA using qPCR. Our data showed that FOXA1 was highly enriched at the IL-8 promoter and PSA enhancer, but not at the negative control gene, in both primary and metastatic PCa tissues (Figure 3h ). To further demonstrate that FOXA1 occupancy at the IL-8 promoter indeed regulates its transcriptional activity, we cloned the IL-8 promoter region into the pGL4.1[luc2] vector. Luciferase assay revealed that FOXA1 knockdown led to a marked increase of the transcriptional activity of the IL-8 promoter (Supplementary Figure 2) . In good agreement of this, ChIP-qPCR showed significantly enhanced occupancy by active RNA polymerase II (PolII p-Ser-5) and H3K4me3 at the IL-8 promoter upon FOXA1 knockdown (Supplementary Figure 3) . Thus, we conclude that FOXA1 occupies the IL-8 promoter to directly inhibit its transcription. Next, we attempted to examine whether IL-8 is involved in FOXA1-mediated MAPK/ERK activation.
IL-8 mediates FOXA1 loss-induced MAPK/ERK activation and NE differentiation
To determine whether IL-8 induces ERK phosphorylation and ENO2 expression, we performed IL-8 knockdown in NE-like PC-3M cells. qPCR with reverse transcription (qRT-PCR) analysis demonstrated significant decreased expression of NE marker ENO2 (Figure 4a ). Moreover, western blot analysis confirmed ENO2 downregulation at the protein level and also showed substantially decreased amount of pERK following IL-8 knockdown. Exogenous IL-8 stimulation, on the other hand, remarkably induced ENO2 expression (Supplementary Figure 4) , supporting the role of IL-8 in promoting ERK phosphorylation and NE differentiation. To further elucidate that FOXA1 regulation of NEPC is due to secreted IL-8 protein, we collected the conditioned media from LNCaP cells with control pGIPZ or FOXA1 knockdown, which were subsequently utilized to infected with pQCXIH or FOXA1-overexpressing retrovirus followed by 2 weeks of hygromycin selection. Cells were fixed, stained by crystal violet and imaged. (e, f) FOXA1 knockdown induces ENO2 expression. LNCaP (e) and C4-2B (f) cells were infected with control or shFOXA1 lentivirus followed by puromycin selection, and then analyzed by qRT-PCR and western blotting. Error bars indicate n = 3, mean ± s.e.m., **P o0.001. (g) FOXA1 was stably overexpressed in PC-3M cells using FOXA1 retrovirus followed by 2 weeks of hygromycin selection. Error bars indicate n = 3, mean ± s.e.m., *P o0.05.
stimulate fresh LNCaP cells. Interestingly, LNCaP cells stimulated with conditioned medium from the FOXA1-depleted cells, which we have previously shown to express eightfold more IL-8 protein (Figure 3d ), exhibited cellular phenotype resembling NE transdifferentiation (Figure 4b) . Concordantly, qRT-PCR and western blot analysis demonstrated substantially increased amount of ENO2 expression and ERK phosphorylation in the cells stimulated with shFOXA1-conditioned media versus those treated with control media (Figure 4c ). Most importantly, the effect is blocked, at least partially, by the MAPK/ERK inhibitor SCH772984, 39 suggesting that IL-8 induces NE differentiation through MAPK/ERK activation (Figure 4d ). Finally, we attempted to examine whether this IL-8/pERK/ENO2 pathway is involved in mediating FOXA1 loss-induced NE differentiation. LNCaP cells were subjected to knockdown of IL-8 alone, FOXA1 alone or both. qRT-PCR analysis confirmed that IL-8 knockdown inhibited ENO2 expression and, importantly, abolished FOXA1 lossinduced ENO2 (Figure 4e) . In good agreement with this, western blot showed that concurrent IL-8 knockdown markedly reduced ENO2 protein level in FOXA1-depleted LNCaP cells. Therefore, IL-8 upregulation is required for FOXA1 loss-induced NE differentiation of PCa cells.
FOXA1 is downregulated in NEPC and negatively correlated with ENO2 expression To further demonstrate that FOXA1 plays a role in PCa progression to NEPC, we took advantage of a recently generated NEPC xenograft mouse model. 40 Comparatively, gene expression analysis revealed that FOXA1 is indeed downregulated in LNCaP-derived NEPC xenografts relative to its adenocarcinoma counterparts, whereas ENO2 as expected is strongly upregulated in NEPC xenografts (Figures 5a and b) . Moreover, immunohistochemistry staining of FOXA1 and NE marker synaptophysin in continuous xenograft tissue sections demonstrated an overall decrease of FOXA1 in NEPC tumors, especially in areas with strong synaptophysin staining (Figure 5c) .
Next, to test this in PCa patients, we examined the expression levels of FOXA1 and ENO2 in a number of large PCa gene expression profiling data sets [41] [42] [43] [44] [45] as well as The Cancer Genome Atlas data set. Importantly, we observed highly significant negative correlation between the expression of FOXA1 and NE markers in primary PCa tissues (Figure 5d ; Supplementary Figure 5) . Further, to specifically examine this regulation in NEPC, we analyzed the Beltran et al. data set that compared gene expression of 7 NEPC tissues with 30 prostate adenocarcinoma using RNA sequencing. 32 We found that FOXA1 mRNA level is FOXA1, a regulator of neuroendocrine prostate cancer J Kim et al indeed much lower in NEPC compared to primary PCa samples, whereas ENO2 expression was strongly upregulated in NEPC (Figure 5e ). Moreover, taking advantage of another RNA sequencing data set that has recently become available, 33 we found that FOXA1 is also significantly downregulated in NEPC relative to CRPC, whereas as positive control ENO2 expression was increased (Figure 5f ). Altogether, our data showed that FOXA1 expression is lost in NEPC and is negatively correlated with the expression of NE marker ENO2, strongly supporting the role of FOXA1 in preventing NEPC progression in clinical PCa.
DISCUSSION
FOXA1 is a transcription factor that is indispensable for prostate development and epithelial cell differentiation. 46 For a long time, FOXA1 was considered as a pioneer factor that recruits the AR to lineage-specific genomic loci to turn on prostatic gene expression. 47 More recently, dual roles of FOXA1 have been reported in its regulation of AR including both pioneering and reprogramming effects. 48, 49 In addition, in the context of CRPC, we showed that FOXA1 plays an inhibitory role in restricting the activity of residual AR in androgen-depleted cells, while FOXA1 loss unleashes an androgen-independent AR program. 28 Moreover, we reported an androgen-independent function of AR wherein it directly inhibits SLUG gene transcription and thus hinders epithelial-to-mesenchymal transition. 29 Along this line of research, in the present study, we demonstrated that FOXA1 inhibits IL-8 transcription through direct occupancy at and regulation of its promoter. The concept of FOXA1 as a transcriptional repressor is new and the molecular mechanisms involved are yet to be defined. We predict that FOXA1, as a chromatin opening factor, might facilitate the recruitment of corepressors to the regulatory elements of some specific genes that are to be maintained in a silenced mode in prostate cells, such as those involved in epithelial-to-mesenchymal transition and NE differentiation. Functionally, we showed that FOXA1 is able to and IgG ChIP were performed in LNCaP cells. PSA enhancer is used as a positive control, whereas KIAA0066 a negative control gene that is not enriched by anti-FOXA1. Error bars indicate n = 3, mean ± s.e.m., *P o0.05. (g) FOXA1 ChIP was performed in LNCaP cells with control or FOXA1 knockdown, followed by qPCR analysis. (h) FOXA1 occupies the IL-8 promoter in human prostate cancer tissues. FOXA1 ChIP was performed in one localized (PCA) and one metastatic (MET) prostate cancer tissues. Input and ChIP-enriched DNA were amplified using ligation-mediated PCR. Equal amount of amplicons were utilized to determine relative enrichment over input. Error bars indicate n = 3, mean ± s.e.m., *Po 0.05. prevent NE differentiation of PCa cells, being consistent with its central role as an epithelial factor.
As a prostatic transcription factor, FOXA1 is often expressed at high levels in the prostate along with the AR. We and others have shown earlier that FOXA1 is transiently upregulated in localized PCa, but ultimately downregulated in CRPC, prominently at mRNA levels. 28, 48 In this study, we found that FOXA1 is further downregulated in NEPC. This disease stage-dependent expression of FOXA1 is likely associated with its dual roles in promoting cell growth but inhibiting epithelial-to-mesenchymal transition and NE differentiation, which are the dominating characteristics of primary and CRPC/NEPC tumors, respectively. Notably, although epithelial-to-mesenchymal transition is required for tumor dissemination, metastatic tumors that have successfully homed into distal organs will need to go through mesenchymal-toepithelial transition to regain proliferation. 50, 51 Likewise, NE cells are known to have low growth rate but NEPC or small-cell carcinoma cells grow rapidly and are thus highly aggressive. 52 During these reversal processes, it may be a necessity for FOXA1 re-expression. Consequently, we predict that FOXA1 levels may be tightly regulated through the disease transitions and might not always been downregulated in all CRPC and NEPC tumors. The level of FOXA1 expression in these tumors may be dependent on or indicative of their respective growth and differentiation status. It would be interesting to determine in future studies whether/when FOXA1 expression is re-gained after tumor cells have successfully completed metastasis and/or NE differentiation.
High-throughput molecular characterization has revealed that NEPC patients harbor various genetic aberrations, such as MYCN and AURKA amplification, and epigenetic de-regulations. 32, 33, 53 Upon identification of these genetic alterations, a phase II clinical trial for AURKA inhibitor, MLN8237, has been initiated for NEPC and small-cell carcinoma patients. In future studies, it would be interesting to test whether FOXA1 loss and function are linked with such genetic and epigenetic aberrations. As delineated in Figure 6 , in this study, we demonstrate FOXA1 loss as an important upstream regulator of IL-8, one of the most extensively studied genes in NEPC. 5 Further, we showed that this is mediated by IL-8-activated ERK phosphorylation, suggesting that IL-8-neutralizing antibodies, CXCR2 antagonists and MEK/ERK inhibitors may hold great promise for the treatment of late-stage castration-resistant PCa. LNCaP cells were subjected to the knockdown of IL-8 and FOXA1 alone or in combination. ENO2 transcript and protein levels were examined by qRT-PCR (e) and western blotting (f). *P o0.05 and **Po0.001.
MATERIALS AND METHODS
Cell lines
PCa cell lines LNCaP and PC-3M were obtained from American Type Culture Collection (Manassas, VA, USA) and C4-2B cells were a gift from Dr Arul Chinnaiyan. All cell lines were authenticated and free of mycoplasma. Cells were cultured in RPMI 1640 with 10% fetal bovine serum. FOXA1 stable knockdown cells were created by infecting shFOXA1 lentivirus followed by 1 week of puromycin selection. FOXA1 stable overexpress cells were created by infecting FOXA1 overexpress retrovirus followed by 2 weeks of hygromycin selection.
Conditioned media
LNCaP FOXA1 stable knockdown and control cells were made and media were incubated for 1 week prior to collection. Collected media were spin Figure 5 . FOXA1 is downregulated in NEPC and negatively correlated with ENO2 expression. (a, b) FOXA1 mRNA (a) and protein (b, c) levels decrease in LNCaP-derived NEPC xenografts. LNCaP (AdPC) were LNCaP xenografts (n = 3) collected at the castration-resistant stage, when serum PSA concentrations recurred above the pre-castration levels. These tumors remain adenocarcinoma phenotype. LNCaP (NEPC) xenografts (n = 3) were obtained from SRRM4-expressing LNCaP cells that were implanted in castrated nude mice. Phenotypical and histology analyses were reported previously. 40 These tumors were castration resistant and had been maintained in castrated mice for three generations with low/no AR and PSA expression. NCI-H660 is an NEPC cell line used as a positive control. (c) FOXA1 protein is decreased in NEPC tumors and negative correlated with NE biomarker. Immunohistochemistry was performed on LNCaP (AdPC) and LNCaP (NEPC) xenografts with indicated antibodies and H&E staining. Representative images in the same field of the tumor were shown. Black arrows indicate areas of FOXA1 loss. Scale bars = 100 μm. (d) FOXA1 and ENO2 mRNA expression is negatively correlated. Six previously published prostate cancer gene expression data sets [41] [42] [43] [44] [45] were downloaded from the GEO database. The expression values of FOXA1 and ENO2 are retrieved and plotted. (e, f) FOXA1 is downregulated in NEPC, wherein ENO2 is upregulated. Previously published RNA-seq data of 37 PCa 32 (e) and 49 CRPC 33 (f) with or without neuroendocrine differentiation were obtained from cBioPortal. 57, 58 The expression values of ENO2 and FOXA1 were plotted comparing NEPC with PCa or CRPC.
Epithelial Cells
Neuroendocrine Cells Figure 6 . A model depicting FOXA1 regulation of neuroendocrine differentiation. FOXA1 loss in prostate adenocarcinoma induces the expression of IL-8, which activates MAPK/ERK signaling, leading to neuroendocrine differentiation marked by high ENO2 expression.
down to remove dead cells and 10 mM HEPES and 1 × glutamax were supplemented prior to use.
Plasmids and small interfering RNA FOXA1 stable knockdown pGIPZ lentiviral shRNAmir construct (Clone ID #V2LHS_16780) was obtained from Open Biosystems (Pittsburg, PA, USA). IL-8 stable knockdown construct was generated by inserting oligos (CGAACTTTAATTTCAGGAA) to the pLKO.1 backbone. FOXA1 overexpression construct was generated by cloning full-length FOXA1 into pQCXIH (Clontech, Mountain View, CA, USA). IL-8 promoter with FOXA1-binding region was amplified by PCR from HEK293T genomic DNA and cloned into pGL4.1[luc2] luciferase reporter vector (Promega, Madison, WI, USA).
Western blots, ChIP, ELISA and antibodies Western blotting analyses were performed using standard protocols. Antibodies used were as follow: anti-FOXA1 (ab23738, Abcam, Cambridge, UK), anti-NSE (M0873, Dako, Santa Clara, CA, USA), anti-pERK1/2 (4370 S, Cell Signaling, Danvers, MA, USA), anti-ERK1/2 (0192 S, Cell Signaling), anti-AR (06-680, Millipore, Kankakee, IL, USA) and anti-GAPDH (ab9385, Abcam). ChIP was performed as previously described. 54 Antibodies used include anti-FOXA1 (ab23738, Abcam), anti-RNA PolII p-Ser5 (04-1572, Millipore) and anti-H3K4me3 (04-745, Millipore). ELISA was performed using Human IL-8 ELISA kit II following the manufacture's protocol (550999, BD Bioscience, San Jose, CA, USA).
Luciferase assay
Luciferase assay was performed as previously described. 55 In brief, pGL4.1 [luc2]-IL-8 was transfected along with Renilla internal control into LNCaP shCtrl or shFOXA1 stable cells. Luciferase assays were performed 48 h after the transfection.
Microscopy and morphology analysis
Fluorescent and crystal violet images were taken using Olympus CKX41 (Waltham, MA, USA). Cell morphologies were determined manually: green fluorescent protein-positive cells with two or more branches were considered NE phenotype and cells with rounded shapes were considered epithelial.
Quantitative PCR assay
Quantitative PCR was conducted by Bullseye Evagreen qPCR 2X master mix (MIDSCI, Valley Park, MO, USA) using StepOne Plus Realtime PCR system (Applied Biosystems, Foster City, CA, USA). All primers were designed using Primer3 and synthesized by Integrated DNA Technology (IDT, Coralville, IA, USA). All primers used in this study are listed in Supplementary Table1.
Immunohistochemistry
Paraffin-embedded PCa tissue blocks were from the Vancouver Prostate Centre Tissue Bank. Patient consent was reviewed and approved by the University of British Columbia Clinical Research Ethics Board (certificate no. H09-01628). Immunohistochemical staining was conducted as previously described 56 using the Ventana DiscoverXT Autostainer (Ventana Medical System, Oro Valley, AZ, USA) with enzyme labeled biotin streptavidin system and solvent-resistant DAB Map kit (Ventana Medical System). Antibodies used in immunohistochemistry include anti-FoxA1 (Abcam; ab23738), anti-synaptophysin (Abcam; ab32127), anti-chromogranin A (Millipore; MAB5268) and anti-IL-8 (R&D systems, Minneapolis, MN, USA).
Statistical methods
All the experiments were performed at least in three biological replicates. All the figures shown are mean ( ± s.e.m.) of technical replicates from one representative experiment. All statistical testing was done using two-sided t-test unless otherwise noted.
Bioinformatics analysis
Correlation plot was generated using R ggplot 2 package. Geom_point function was used to create scatterplots and stat_smooth function was used to find the pattern by linear smooth methods. Correlation coefficient (r) and P-values are calculated and shown on top left.
